A Role for Mucolytics and Expectorants in Aiding Inhaled Therapies in Asthma? [Response To Letter]
- PMID: 34675596
- PMCID: PMC8517631
- DOI: 10.2147/JIR.S341547
A Role for Mucolytics and Expectorants in Aiding Inhaled Therapies in Asthma? [Response To Letter]
Conflict of interest statement
HR reports speaker and consultancy fees from AstraZeneca, GlaxoSmithKline, Teva, and Novartis and research grant funding from GlaxoSmithKline. WCGF reports ownership of AstraZeneca, GlaxoSmithKline And BioNTech shares. The aforementioned authors report no other potential conflicts of interest for this communication. AK and RJK have no relevant conflicts of interest for this communication to declare.
Comment on
-
Recent Insights into the Management of Inflammation in Asthma [Letter].J Inflamm Res. 2021 Sep 14;14:4603-4604. doi: 10.2147/JIR.S337690. eCollection 2021. J Inflamm Res. 2021. PMID: 34548806 Free PMC article. No abstract available.
References
Publication types
LinkOut - more resources
Full Text Sources
